Tracy Tomlinson, 58, is the first person worldwide to receive ZI-MA4-1, an experimental "off-the-shelf" cell therapy at The Christie in Manchester. The treatment uses donor natural killer cells engineered to target tumours expressing the MAGE-A4 protein and is being tested in ovarian, lung, sarcoma and head and neck cancers. The early-phase trial focuses on safety; Tomlinson has had three infusions and may receive more depending on scans.
World First: Woman Receives Experimental Off-The-Shelf Cancer Cell Therapy ZI-MA4-1
Tracy Tomlinson was diagnosed with ovarian cancer in 2020 [PA Media]
A 58-year-old woman with advanced ovarian cancer has become the first person in the world to receive an experimental off-the-shelf cell therapy called ZI-MA4-1 as part of an early-phase clinical trial.
Treatment and Trial
Tracy Tomlinson was administered the therapy at The Christie hospital in Manchester. The trial, led by The Christie with a site at the Royal Marsden in London, will evaluate ZI-MA4-1 in ovarian, lung, sarcoma and head and neck cancers. The study (Zima-101) is an early-stage, safety-focused trial; many participants have limited treatment options remaining.
Tracy Tomlinson says she appreciates "the smallest of things that we take for granted" after her diagnosis [PA Media]
How ZI-MA4-1 Works
The therapy combines two immune-based strategies. It uses donor-derived natural killer (NK) cells whose receptors have been engineered to recognise tumours that express the protein MAGE-A4. By arming NK cells to 'see' MAGE-A4, researchers aim to direct a potent immune attack against tumour cells. Because ZI-MA4-1 is manufactured in advance from donor material, it is described as an "off-the-shelf" product — hundreds of doses can be produced from a single batch, potentially expanding access and reducing cost compared with bespoke cell therapies.
Patient Experience
Tomlinson, from Chadderton in Oldham, was diagnosed in 2020 with stage 3C ovarian cancer and has undergone surgery and multiple lines of chemotherapy. She has so far received three infusions of ZI-MA4-1 and may receive additional doses depending on scan results. She said she chose to take part almost immediately and acknowledged it was "a little bit scary" to be the first recipient, but added that she hopes her participation will help others in future.
Tracy Tomlinson said she hopes by taking part in the study she can "make a difference" [PA Media]
"Every day that I wake up is a positive. You've got to have hope," Tomlinson said, noting how her diagnosis has made her appreciate small everyday things and the people around her.
Comments From Clinicians and Developer
Prof Fiona Thistlethwaite, consultant medical oncologist at The Christie, described the study as "an exciting step forward in efforts to develop new treatment options for people with advanced solid tumours," while Dr Jon Lim, a consultant in advanced immunotherapy and cell therapy, called the approach "very exciting" and explained that the treatment involves placing engineered donor immune cells into a recipient so they can recognise the cancer.
Namir Hassan of Zelluna, the Norwegian biotech company developing ZI-MA4-1, called Tomlinson's first dose a "landmark moment."
Context
Ovarian cancer remains challenging to treat: only around 15% of women survive five years or more after diagnosis. As with all early-phase studies, the primary goal is to evaluate safety and tolerability; effectiveness will be assessed in later trial stages.
Note: This report summarises trial participation and early developments. Patients considering clinical trials should consult their specialist teams for personalised medical advice.
Help us improve.
